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ABSTRACT
Deciphering the crosstalk between a host cell and a
virus during infection is important not only to better
define viral biology but also to improve our under-
standing of cellular processes. We identified the
FANC pathway as a helper of viral replication and
recombination by searching for cellular targets
that are modified by adenovirus (Ad) infection and
are involved in its outcome. This pathway, which is
involved in the DNA damage response and check-
point control, is altered in Fanconi anaemia, a rare
cancer predisposition syndrome. We show here that
Ad5 infection activates the FANC pathway inde-
pendent of the classical DNA damage response.
Infection with a non-replicating Ad shows that the
presence of viral DNA is not sufficient to induce
the monoubiquitination of FANCD2 but still acti-
vates the DNA damage response coordinated
by phospho-NBS1 and phospho-CHK1. E1A expres-
sion alone fails to induce FANCD2 monoubiquitina-
tion, indicating that a productive viral infection and/
or replication is required for FANC pathway activa-
tion. Our data indicate that Ad5 infection induces
FANCD2 activation to promote its own replication.
Specifically, we show that FANCD2 is involved in the
recombination process that accompanies viral DNA
replication. This study provides evidence of a DNA
damage-independent function of the FANC pathway
and identifies a cellular system involved in Ad5
recombination.
INTRODUCTION
Cellular infection by DNA viruses can be seen as a
dynamic interplay: on the one side, the virus tries to ma-
nipulate host cell activities to allow its own replication,
while on the other, the cell activates defence responses to
counteract viral expansion. Thanks to the analysis of their
interactions with the host, viruses have proved to be a
useful tool in understanding cellular processes, such as
replication, apoptosis and the immune response.
Adenovirus (Ad) is a double-stranded DNA virus that
promotes cell-cycle progression and unprogrammed DNA
replication and generates a huge amount of exogenous
DNA for the host cell to deal with (1). The Ad genome
is unique among animal viruses with double-stranded
DNA genomes because of its linear nature; following
infection, double-stranded DNA termini are sensed as
double-stranded breaks (DSBs) by the host cell and are
able to activate the DSB repair machinery. However, this
response is only detected in the absence of the E4 region
of Ad (2,3). Infection with a E4 virus results in the
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not occur during the wild-type (wt) Ad5 infection (4); this
demonstrates that the viral genome is a substrate for
DSB repair and that proteins from the E4 region are ne-
cessary to block the DNA repair response. The E4-derived
proteins target the MRE11:RAD50:NBS1 (MRN)
complex, a sensor and central player in the response to
DSBs (5,6). This targeting is accomplished through two
mechanisms: the redistribution of the MRN complex to
nuclear speckles and its targeting for proteasome-
mediated degradation (3). The MRN complex is neces-
sary to fully activate both ataxia-telangiectasia mutated
(ATM)- and ATM-Rad3-related (ATR)-dependent
signalling, which orchestrate the DNA damage response
(DDR) (7). Consequently, through the dismantling of the
MRN complex, Ad abrogates a major host DNA damage
defence (2,8). However, many other viruses, including
SV40, HIV and EBV, exploit the DDR to their own
advantage (9).
In addition to several other targets, ATR signalling is
involved in the activation of the FANC pathway (10–12),
which is thought to coordinate the stabilization and
recovery of spontaneous and DNA damage-induced rep-
lication fork stalling with checkpoint functions (13–15).
The FANC pathway consists of a network of proteins,
13 of which are encoded by genes mutated in the rare
genetic disease Fanconi anaemia (FA) (15), which is
characterized by bone marrow failure, genomic instabil-
ity and a predisposition to cancer. FA cells are hyper-
sensitive to DNA interstrand crosslink (ICL)-inducing
agents, such as the anticancer drugs cisplatin and
mitomycin C (MMC) (15–17). Genomic instability and
hypersensitivity to ICLs strongly suggest a role for the
FANC pathway in the DDR. During S phase or in
response to DNA damage, eight of the FANC proteins
(FANCA, -B, -C, -E, -F, -G, -L and -M) that form
the FANC core complex mediate the monoubiquit-
ination of both FANCD2 (18) and FANCI (19).
Following monoubiquitination, the FANCD2/FANCI
dimer recruits FAN1 (20) and relocalizes to nuclear
foci with proteins implicated in the repair of stalled repli-
cation forks and DSBs through recombination-dependent
mechanisms, including gH2AX, FANCD1/BRCA2,
BRCA1, BLM, RAD51, RAD51C and the MRN
complex (21–28).
In this study, we examined whether Ad5 infection
targets the FANC pathway, and we show here that Ad5
infection induces FANCD2 monoubiquitination and
recruitment to viral replication centres. We demon-
strate that FANCD2 monoubiquitination requires Ad5
replication, but that this event is independent of the
classical cellular DDR. Accordingly, infection with a
non-replicating virus fails to induce FANCD2 mono-
ubiquitination while still inducing the DDR coordinated
by phospho-NBS1 and phospho-CHK1. Finally, our
experiments indicate that the absence of FANCD2
impacts the kinetics of viral replication and affects viral
recombination. Our data provide evidence of a DNA
lesion-independent function of the FANC pathway and
identify a cellular system involved in Ad5 recombination.
MATERIALS AND METHODS
Cell lines and culture conditions
Human umbilical vein endothelial cells (HUVECs)
obtained from healthy donors, as previously described
(29), were cultured in EBM-2 (Lonza) supplemented ac-
cording to the manufacturer’s instructions. The FANC
pathway-proﬁcient HeLa and MRC5 cell lines and the
FA cell lines PD20 (FANCD2
 / ), PD20 3.15 (a PD20-
derived cell line expressing a wt FANCD2), PD20-K561R
(a PD20-derived cell line ectopically transfected with a
non-monoubiquitinable FANCD2), PD331 (FANCC
 / ),
PD331-corrected (a PD331-derived cell line expressing a
wt FANCC) and PD220 (FANCA
 / ) were all cultured in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supple-
mented with 12% fetal calf serum (FCS; Dutcher) and
2.5mg/ml plasmocin (Amaxa Biosystems). The FA cell
lines were provided by the Oregon Health & Science
University Fanconi Anemia Cell Repository (Portland,
Oregon). To produce HeLa cells that stably expressed
ATM or ATR small hairpin RNAs (shRNAs), a
second-generation recombinant lentiviral vector cloned
with an shRNA-encoding sequence was produced as pre-
viously described (30). The following oligonucleotide se-
quences were used as shRNA sequences: ATM, 50GATCC
CCGGATTTGCGTATTACTCAGTTCAAGAGACTG
AGTAATACGCAAATCCTTTTGGAAA30 (sense) and
50AGCTTTTCCAAAAAGGATTTGCGTATTACTCA
GTCTCTTGAACTGAGTAATACGCAAATCCGGG30
(antisense), and ATR, 50GATCCCCGGCGTCGTCTCA
GCTCGTCTTCAAGAGAGACGAGCTGAGACGAC
GCCTTTTTGGAAA30 (sense) and 50AGCTTTTCCAA
AAAGGCGTCGTCTCAGCTCGTCTCTCTTGAAGA
CGAGCTGAGACGACGCCGGG30 (antisense). As a
negative control of transfection, a lentiviral vector ex-
pressing shRNA with no sequence homology to any
target in the human genome (shScrambled) was used:
50CGCGTCCCCAAGACTTATCGTCCACAAGTTCA
AGAGACTTGTGGACGATAAGTCTTTTTTTGG
AAAT30 (sense) and 50CGATTTCCAAAAAAAGACTT
ATCGTCCACAAGTCTCTTGAACTTGTGGACGAT
AAGTCTTGGGGA30 (antisense). Transduced cells were
maintained in culture in the presence of 2mg/ml
puromycin.
Viruses, probe preparation and drugs
The Ad5 (provided by M. Crescenzi, ISS, Rome, Italy)
and Ad2 (provided by P. Boulanger, Universite ´ Lyon,
Lyon, France) viruses were propagated in HeLa cells,
AdGFP (a E1E3 Ad whose E1 region has been replaced
with GFP) and mutE1A13s (dl520, Ad5-derived; M.
Crescenzi, ISS, Rome, Italy) were propagated in 293
cells (31) and E4 (dl1004, Ad5-derived; provided by G.
Ketner, John Hopkins University, Baltimore, MD, USA)
was propagated in W162 medium (32).
Two successive rounds of caesium chloride equilibrium
centrifugation were performed to purify the viral prepar-
ations, and the stocks were then titrated according to
optical units (OPU), high-performance liquid chromatog-
raphy (HPLC) and plaque-forming units (PFU) as
5460 Nucleic Acids Research, 2011,Vol.39, No. 13previously described (33–35). All viral stocks exhibited a
viral particle to infectious unit ratio (OPU/PFU) between
10 and 40. Quantitative polymerase chain reaction
(q-PCR) was used to determine the purity of mutant
viral stocks as previously described (36), and the stocks
were virtually pure, with <0.003% contamination. To
prepare the probe used in the Southern blot analysis,
viral DNA from puriﬁed Ad2 stock was extracted with
the Nucleospin Tissue kit (Macherey-Nagel) according
to the manufacturer’s instructions. The puriﬁed DNA
was then used to prepare the probe using PCR with the
DIG labelling system (Roche) according to the manufac-
turer’s instructions, and oligonucleotides were used to
amplify the region between nucleotides 13441 and 14961
(NCBI Reference Sequence: AC_000007.1). Hydroxyurea
(HU) was purchased from Sigma and resuspended in water.
Infections and transient transfections
For all infections, cells were infected in a low volume of
DMEM supplemented with 2% FCS 24h after plating.
After incubation for 1h at 37 C, the virus was removed
by aspiration and multiple washes, and fresh medium was
added to the cells. In HUVECs, infections were performed
in the same media used for culture because it already con-
tained 2% FCS. For transfections, cells were grown
in six-well plates. For E1A transfection, pCMVE1A12S
and pCMVE1A13S plasmids (kindly provided by M.
Crescenzi, ISS, Rome, Italy) were transfected alone or in
combination using Fugene (Roche) according to the
manufacturer’s instructions. FANCD2 expression was
knocked down using small interfering RNA (siRNA)
transfection using duplexed siRNA (Eurogentec)
directed against the sequence 50GGAGAUUGAUGGU
CUACUA30. As a negative control, luciferase siRNA
with the sequence 50CGUACGCGGAAUACUUCGA30
was used. The siRNAs were resuspended in RNase-free
water at 20mM, and cells were transfected using
Oligofectamine (Invitrogen) according to the manufac-
turer’s protocol for adherent cells.
RNA and DNA extraction and preparation
Total RNA was extracted using the RNeasy kit (Qiagen)
according to the manufacturer’s instructions, and cDNA
retrotranscription was performed using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems) ac-
cording to the manufacturer’s instructions. Total DNA
was extracted with the Nucleospin Tissue kit (Macherey-
Nagel) according to the manufacturer’s instructions. RNA
and DNA quantiﬁcation was performed using an ND-
1000 spectrophotometer (NanoDrop Technologies).
Cell lysates and immunoblot analysis
At the indicated time points, infected cells were lysed in
RIPA buffer [50mM Tris–HCl, pH 7.4, 150mM NaCl,
1mM PMSF, 1mM ethylenediaminetetraacetic acid
(EDTA), 1% Triton X-100, 1% sodium deoxycholate,
0.1% sodium dodecyl sulphate (SDS), complete mini
EDTA-free protease inhibitor cocktail tablets (Roche)
and PhosStop phosphatase inhibitor cocktail tablets
(Roche)] for 30min on ice. The soluble protein
concentration was then determined using the Bradford
assay (Bio-Rad), and the lysates were sonicated after
the addition of Laemmli buffer. A total of 20mgo f
total protein was separated using SDS–polyacrylamide
gel electrophoresis and transferred onto a nitrocellulose
membrane (Whatman). Membranes were blocked in 5%
low-fat milk in TBST buffer (10mM Tris–HCl, pH 8.0,
150mM NaCl and 0.1% Tween 20) followed by primary
antibody incubation overnight (O/N) at 4 C. The follow-
ing proteins were then probed using their respective
antibodies at the indicated dilution: FANCD2 (1:2000,
ab2187, rabbit), pS343NBS1 (1:2000, ab75778, rabbit)
and vinculin (1:400, ab18058, mouse) (Abcam); gH2AX
(1:1000, 05-636, mouse) and NBS1 (1:1000, 07-317,
rabbit) (Millipore); actin (1:1000, sc-1615, goat), ATR
(1:500, sc-28901, rabbit), CHK1 (1:400, sc-7898, rabbit)
and b-tub (1:500, sc-101527, mouse) (Santa Cruz
Biotechnology); E1A (1:600, MS-587 - P1, mouse;
Labvision Corporation); pS345CHK1 (1:1000, 2348,
rabbit; Cell Signaling); ATM (1:500, 2C1, mouse;
GeneTex); and Ad5 (L5 1:2000, rabbit). Immunoreactive
proteins were labelled using horseradish peroxidase-
conjugated antibodies (Santa Cruz Biotechnology),
revealed using the enhanced chemiluminescence system
(ECL plus, Pierce) and visualized with a Gene Gnome
gel documentation system (Syngene).
BrdU incorporation for ﬂow cytometry assay
At the indicated time points, media was aspired and a low
amount of fresh media with 10mM BrdU was added to
the cells. After 1h at 37 C, cells were collected by
trypsinization, washed in phosphate-buffered saline
(PBS) and ﬁxed in cold EtOH 70%. At least 24h after ﬁx-
ation, cells were washed in PBS and denatured in HCl 2N
for 15min at room temperature (RT). Cells were then
washed in PBS and PBS/0.1% bovine serum albumin
(BSA)/0.2% Tween and incubated with anti-BrdU
antibody (1:50, mouse monoclonal, Becton-Dickinson)
for 30min. After washes in PBS/0.1% BSA/0.2%
Tween, cells were incubated with ﬂuorescein isothiocyan-
ate (FITC)-conjugated anti-mouse antibody (1:50,
DAKO) for 30min in the dark. Finally, the cells were
washed in PBS/0.1% BSA/0.2% Tween, then PBS and re-
suspended in PBS containing RNAse (100mg/ml, SIGMA)
and Propidium Iodide (PI, 50mg/ml, Invitrogen). Samples
were analysed with a FACScalibur instrument (Becton
Dickinson). Twenty thousand events were acquired and
populations were gated to exclude cell debris and
doublets. Acquired samples were then analysed using the
FlowJo software 8.8.6 (Tree Star Inc.)
Immunoﬂuorescence
Cells were grown on coverslips in six-well plates for 24h
before infection. At the indicated time points post-
infection, the cells were ﬁxed with 4% paraformaldehyde
for 10min at RT, rinsed with PBS and permeabilized with
Triton buffer (0.5% Triton X-100, 20mM HEPES,
pH 7.9, 50mM NaCl, 3mM MgCl2 and 300mM
sucrose) for 10min on a rocking platform. Cells were
then blocked in a solution of PBS/3% BSA/0.05%
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antibody. The following antibodies were used: FANCD2
(1:1000, ab2187, rabbit) and gH2AX (1:500, ab2893,
rabbit) (Abcam), DBP (1:1000; 37.3, mouse; Dr D.F.
Klessig) and CPD (1:200, mouse; Cosmo Bio). The cells
were then washed with PBS/3% BSA/0.05% Tween and
incubated for 1h at RT with anti-mouse Alexa Fluor 488-
and anti-rabbit Alexa Fluor 594-conjugated secondary
antibodies (Invitrogen) followed by sequential washing
in PBS/3% BSA/0.05% Tween, PBS and dH2O. After
drying the preparations, the coverslips were mounted on
glass slides with DAPI Vectashield (Vector Laboratories).
All preparations were analysed using an Olympus BX-50
ﬂuorescence microscope equipped with an Orca-Er camera
(Hamamatsu). Grey-scale digital images were collected
separately using the SimplePCI software and converted
for Photoshop (Adobe Systems).
q-PCR
To quantify viral DNA and gene expression levels,
gene-speciﬁc primers were designed with Primer Express
software (Applied Biosystems) for the ampliﬁcation of
E1A (Ad5 nt 697–778) and L1 (Ad5 nt 12322–12423).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as an internal standard in all reactions, using
the following oligonucleotides for ampliﬁcation: forward
(50-TGGGCTACACTGAGCACCAG-30) and reverse
(50-GGGTGTCGCTGTTGAAGTCA-30). All reactions
were performed and analysed as previously described (36).
DNA analysis using Southern blot
Analysis of the production of Ad recombinants was per-
formed as described by Young and Silverstein (37).
Brieﬂy, 42h post-infection (h.p.i.), the viral DNA was ex-
tracted from infected cells with a modiﬁed HIRT extrac-
tion procedure (38), digested with BamH1 (New England
Biolabs) for 90min at 37 C and then separated using elec-
trophoresis on a 0.6% agarose gel at 50V for 5h. All
successive passages were performed according to the
DIG manual (Roche). Brieﬂy, the gel was depurinated
and denatured, and after neutralisation of the denatur-
ation reaction, the gel was equilibrated in 20  SSC. The
fragmented DNA was transferred onto a nylon membrane
(Amersham) using capillary transfer O/N in 20  SSC.
Transferred DNA was ﬁxed to the membrane for 2h at
80 C, and the membrane was then incubated O/N with the
DIG-labelled probe. After stringent washings, the
membrane was labelled with an anti-digoxigenin alkaline
phosphatase (AP)-conjugated antibody (Roche) and
revealed using a chemiluminescent reaction using CDP-
Star (Roche). The signal was then detected with the
Gene Gnome apparatus, and the signal intensities were
quantiﬁed using Genetools software (Syngene).
Statistical analysis
The results are reported as the mean of at least three in-
dependent experiments, with error bars showing the
standard error. Differences were considered signiﬁcant
when P<0.05, as calculated using the paired sample t-test.
RESULTS
Ad5 infection induces FANC core-dependent FANCD2
monoubiquitination
One of the strategies used by Ad to reprogram cellular
activities to optimize its own replication is to dismantle
part of the cellular DDR via MRE11, NBS1 and RAD50
degradation/mislocalization. We therefore investigated
the behaviour of the FANC pathway, another key com-
ponent of the DDR known to play a role in both DNA
repair and S phase checkpoint (11,13–15) following Ad5
infection. To evaluate the activation of the FANC
pathway, we performed immunoblot analysis to investi-
gate the appearance of the lower mobility band of
FANCD2 (FANCD2-L), which corresponds to its mono-
ubiquitinated form (18). We therefore infected both
primary (HUVECs, Figure 1A) and transformed (HeLa,
Figure 1B) cells with Ad5 and observed that while NBS1
and MRE11 were degraded as expected, FANCD2
became monoubiquitinated upon infection (Figure 1A
and B). Because infection with AdGFP (a non-replicating
Ad5 whose E1 region has been replaced with GFP)
induced neither FANCD2 monoubiquitination nor
NBS1 or MRE11 degradation (Figure 1A and B), we
concluded that FANCD2 monoubiquitination was not a
consequence of the early steps of viral infection, i.e. at-
tachment and internalization, but still required viral gene
expression. We also observed that the extent of FANCD2
monoubiquitination increased with time post-infection
(Figure 1A and B) and that following an infection with
different quantities of Ad5, the levels of monoubiquiti-
nated FANCD2 were proportional to the initial multipli-
city of infection (m.o.i.) (Figure 1C). Viral infection is
thought to push cells into S phase, a situation that could
activate the FANC pathway. However, the level of
FANCD2 monoubiquitination correlated with the initial
m.o.i. rather than with the percentage of BrdU-positive
cells following infection (Figure 1D). It seems, therefore,
that FANCD2 monoubiquitination is linked more to Ad
infection and replication rather than entry and accumula-
tion into S phase of the infected cell population. Finally, it
is known that FANCD2 is monoubiquitinated by a fully
proﬁcient FANC core complex in response to genotoxic
stress (15). Accordingly, FANCD2 monoubiquitination
was absent in FANC core-deﬁcient cells (Figure 1E).
These results indicate that the Ad5-induced mono-
ubiquitination of FANCD2 is FANC core-dependent
and that viral expression is required for this phenomenon
to occur.
Ad5 infection induces a FANC core-dependent
relocalization of FANCD2 at viral replication centres
Monoubiquitinated FANCD2 is targeted to subnuclear
foci in response to DNA damage or replication fork
stalling (28). Because we observed FANCD2 monoubiqu-
itination in response to Ad5 infection, we examined the
subcellular localization of FANCD2 in infected cells.
Indirect immunoﬂuorescence analysis of Ad5-infected
cells demonstrated that FANCD2 localizes at the sites of
viral replication (viral replication centres), as shown by the
5462 Nucleic Acids Research, 2011,Vol.39, No. 13co-localization of FANCD2 with the Ad DNA-binding
protein (DBP), a key protein in Ad replication (39)
(Figure 2A). To exclude the possibility that FANCD2
staining of viral replication centres was an artefact due
to cross-reactivity of the antibody with a viral protein at
this site, we performed the same analysis in the isogenic
cell lines PD20 (FANCD2
 / ) and PD20 3.15 (rescued wt
FANCD2 expression) (Figure 2B). Despite the formation
of viral replication centres in both cell lines, we detected
the co-localization of FANCD2 and DBP only in
FANCD2-expressing cells. Importantly, FANCD2 re-
localization to viral replication centres was also absent
in FANCD2
 /  cells expressing the K561R non-
monoubiquitinable form of FANCD2 (Figure 2B, third
row from the top) and in cells defective for a component
of the FANC core complex (Figure 2C).
Taken together, these results indicate that Ad5 infection
induces a FANC core-dependent monoubiquitination of
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Figure 1. Ad5 infection induces FANC core-dependent monoubiquitination of FANCD2. (A) HUVECs and (B) HeLa cells infected with Ad5 or
AdGFP at an m.o.i. of 1000 OPU and 500 OPU, respectively. Total cell extracts were isolated after infection for the indicated time points and
analysed using western blot with the indicated antibodies. AdGFP indicates a E1E3 Ad5 whose E1 region has been replaced with GFP. (C) HeLa
cells were infected with Ad5 at the indicated m.o.i. and collected at 48h.p.i. Extracted proteins were analysed using western blot using the indicated
antibodies. Ad5 capsid indicates proteins revealed with an antibody raised against the Ad5 capsid. (D) The percentage of the ratio of
monoubiquitinated (L) versus non-monoubiquitinated (S) forms of FANCD2 in Ad5-infected cells relative to mock-infected cells (top). The per-
centage of 5-bromo-20-deoxyuridine (BrdU)-positive cells in Ad5-infected and mock-infected cells (bottom). The proportion of cells in S phase was
monitored using BrdU incorporation and FACS analysis using a speciﬁc anti-BrdU monoclonal antibody. The infection was performed at the
indicated m.o.i. as in (C). (E) FANCA
 /  (PD220), FANCC
 /  (PD331) and FANCC-rescued (PD331+wt FANCC cDNA) human ﬁbroblasts
infected with Ad5 at an m.o.i. of 1000 OPU. Total cell extracts were analysed using western blot with the anti-FANCD2 antibody. M indicates
mock-infected cells. Actin (A and B) and vinculin (C and D) were used as loading controls. The vertical line indicates areas in which the original
blots were cut to eliminate intervening samples.
Nucleic Acids Research, 2011,Vol.39, No. 13 5463FANCD2 that is required for its relocalization to viral
replication centres and that FANCD2 is not essential for
the formation of the latter.
E1A expression is not sufﬁcient to induce FANCD2
monoubiquitination
It has previously been shown that the sole expression of
proteins that are functionally analogous to Ad E1A,
including E7 from human papilloma virus-16 (HPV-16)
and LT from simian virus 40 (SV40), induces FANCD2
monoubiquitination and foci formation (40,41).
Consequently, we investigated the role of E1A expression
in FANCD2 monoubiquitination and nuclear
relocalization.
We transfected the primary E1A splice variants 12S and
13S into HeLa cells and observed that the expression
of the E1A oncoproteins was not sufﬁcient to induce
Mock
Ad5
HeLa cells A
FANCD2
corrected
FANCD2-/-
FANCD2-/-
+ K561R
B Human fibroblasts
FANCC-/-
FANCC
corrected
C Human fibroblasts
Figure 2. Ad5 induces FANC core-dependent localization of FANCD2 at viral replication centres. (A) HeLa cells were infected with Ad5 at
an m.o.i. of 500 OPU. (B) FANCD2
 /  cells (PD20), FANCD2-rescued cells (PD20 3.15, PD20 cells expressing wild-type FANCD2) and
FANCD2
 / +K561R (PD20 cells transfected with a non-monoubiquitinable form of FANCD2) cells were infected with Ad5 at an m.o.i. of
1000 OPU. (C) FANCC-rescued (PD331 cells expressing a wild-type FANCC) and FANCC
 /  (PD331) cells were infected with Ad5 at an
m.o.i. of 1000 OPU. Representative images from cells infected with Ad5 that were processed at 18h.p.i. and analysed using immunoﬂuorescence
using antibodies directed against DBP and FANCD2.
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FANCD2 in subnuclear foci, as observed in cells treated
with hydroxyurea (Figure 3A and B). It, therefore, seems
that contrary to what has been observed for HPV-16 E7
and SV40 LT, expression of the viral oncoprotein E1A
alone is not sufﬁcient to activate the FANC pathway.
In addition, we infected HeLa cells with an Ad5 mutant
that was defective in the expression of the E1A13S splice
variant (mutE1A13S) and only expressed E1A12S, which
can interact with pRb but lacks a domain (CR3) respon-
sible for the transactivation of other viral genes.
Therefore, the mutE1A13S mutant virus is highly defect-
ive in viral expression and replication (42,43). Following
infection with mutE1A13S, we observed that this mutant
was unable to induce FANCD2 monoubiquitination
(Figure 3C).
Altogether, these ﬁndings indicate that E1A expression
alone is not sufﬁcient to induce FANCD2 mono-
ubiquitination and suggest that this event requires either
the expression of other viral proteins or active viral
replication.
FANCD2 monoubiquitination is independent of the
activation of the DDR in the presence of exogenous DNA
It has previously been reported that following DNA
damage, ATR is involved in optimal FANCD2
monoubiquitination and its relocalization to nuclear foci
(10,12). In addition, FANCD2 monoubiquitination
requires CHK1 phosphorylation (44,45), FANCD2 inter-
acts with the MRN complex (46) and the loss or inactiva-
tion of MRN components affects FANCD2 stability (46).
Because viral infection dismantles the MRN complex
and inactivates the ATM/ATR signalling pathways
(Figures 1A and B and 4C) (47), the observed mono-
ubiquitination and relocalization of FANCD2 in
response to Ad5 infection (Figures 1 and 2) appears
uncoupled from the classical cellular DDR. To better
understand the interaction between the FANC pathway
and Ad5 infection, we compared FANCD2 activation in
HeLa cells infected with either Ad5 or an E4-deﬁcient Ad5
(E4) (Figures 3C and 4A). The E4 virus has been
shown to be competent at initiating replication but
unable to inactivate MRN (3). Consequently, replicated
viral genomes are ligated into concatemers that cannot
be packaged into the capsid (2,3). Infection with E4
was accompanied by phosphorylation of NBS1 and
CHK1, indicative of the activation of the cellular DDR
mediated by the ATM/ATR protein kinases (Figure 3C).
Interestingly, FANCD2 was monoubiquitinated to a
lesser extent following E4 infection compared to Ad5
infection (Figure 3C), in which NBS1 and CHK1 phos-
phorylation was inhibited. FANCD2 was also relocalized
to viral replication centres following infection with E4
(Figure 4A). The extent of FANCD2 monoubiquitination
in response to the viral mutants was positively correlated
with the level of production of Ad5 late proteins and did
not simply reﬂect the proportion of cells in S phase, as
shown by the analysis of viral production using an
antibody raised against the mature particle (Ad5 capsid;
Figures 3C and 1C). The lack of NBS1 and CHK1 phos-
phorylation indicates that ATM/ATR signalling is signiﬁ-
cantly affected by Ad5 infection. To further exclude the
requirement of ATM/ATR in Ad-induced FANCD2 acti-
vation, we infected HeLa cells in which ATM or ATR
expression was downregulated by the stable expression
of sequence-speciﬁc short hairpin RNAs (Figure 4B). In
addition, we infected HeLa cells that were transiently
transfected with speciﬁc siRNAs targeting ATR
(Supplementary Figure S1A and B). FANCD2 mono-
ubiquitination and relocalization to viral replication
centres were observed in cells in which ATM/ATR
signalling was impaired by both Ad infection and sh/
siRNA expression. Indeed, the siRNA-mediated ATR
knockdown impaired FANCD2 monoubiquitination and
relocalization to nuclear repair foci in response to HU, but
it did not affect the Ad5-induced monoubiquitination or
FANCD2 relocalization to viral replication centres
(Supplementary Figure S1A and B). Altogether, these
data indicate that FANCD2 monoubiquitination in
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that the reduction in FANCD2 monoubiquitination in
E4-infected cells could be due to either the reduced
amount of exogenous DNA (consequent to a minor viral
ampliﬁcation) or the impaired replication of the mutant
viruses.
To determine whether FANCD2 activation in infected
cells correlated with the amount of exogenous DNA, we
infected HeLa cells with AdGFP at two m.o.i.s: one that
leads to FANCD2 activation in response to Ad5 (500, see
Figure 1B) and another that was 10-times higher. As
shown in Figure 4C and D, although the lower m.o.i.
did not lead to FANCD2 monoubiquitination and focal-
ization, it was sufﬁcient to induce CHK1 and NBS1 phos-
phorylation, indicating activation of the DDR by the
exogenous double-stranded DNA termini. Even at the
higher m.o.i., AdGFP did not induce FANCD2 activa-
tion, despite the toxicity of this amount of viral DNA
on the cells, as indicated through the global degradation
of proteins (Figure 4C) and the altered shape of the
nucleus of the infected cells (Figure 4D).
It has been described that following treatment with
DNA-damaging agents, the subnuclear relocalization of
monoubiquitinated FANCD2 requires the phosphor-
ylated form of the histone variant H2AX (gH2AX) (21).
As observed using western blot (Figure 4E), Ad5 infection
induced the accumulation of gH2AX starting from 18
h.p.i. Because the cellular distribution of DBP changes
during the course of infection and can be used to
identify the different stages of infection (48), we used
indirect immunoﬂuorescence to analyse H2AX phosphor-
ylation and FANCD2 activation in relation to DBP
distribution. While FANCD2 was localized at viral repli-
cation centres early after infection (DBP in discrete
nuclear foci, II; Figure 4F and G), gH2AX was detected
only at later stages of infection (DBP was mostly diffused
throughout the nucleus and the shape of the nucleus was
altered, IV; Figure 4F and G). In fact, the percentage of
cells positive for gH2AX was almost equal to the percent-
age of cells at the latest stage of infection (IV, Figure 4G).
A similar behaviour has previously been reported for
RAD51, a key protein in the strand exchange reaction
of homologous recombination (49). These results suggest
that FANCD2 activation is an early virus-mediated
response, while gH2AX and RAD51 activation seems to
be part of a cell-dependent response, possibly induced by
the accumulation of damaged cellular DNA at later stages
of infection (50).
It has been shown that in ultraviolet (UV)-irradiated
cells, monoubiquitinated FANCD2 accumulates at the
sites of damage (21). To determine whether FANCD2
relocalized to UV-induced lesions after Ad5 infection,
we locally irradiated infected HeLa cells with UV light
and analysed the localisation of FANCD2 and UV-
induced cyclobutane pyrimidine dimers (CPDs) using
immunoﬂuorescence. In the cells in which FANCD2 pre-
sented a pattern similar to that found in Ad-infected
cells (i.e. FANCD2 in viral replication centres), we
observed no FANCD2 relocalization to CPD-positive
sites (Figure 4H). In contrast, nuclei that showed
co-localization of CPDs and FANCD2 showed no signs
of infection, which implies that either viral replication
centres sequester FANCD2 or that dismantling of the
DDR impairs FANCD2 relocalization to the chromatin.
Taken together, these results indicate that FANCD2
monoubiquitination in response to Ad infection is not a
function of the amount of viral DNA. In fact, while a high
amount of viral DNA presenting DSBs is sufﬁcient to
induce the cellular DDR, the presence of free double-
stranded termini is not sufﬁcient per se to induce
FANCD2 monoubiquitination. Furthermore, the localiza-
tion of FANCD2 to viral replication centres following
infection appears to be independent of the classic DDR.
The lack of FANCD2 affects the kinetics of
viral replication
To determine whether the FANC pathway played an
active role in Ad5 infection, we compared Ad5 production
in isogenic FANCD2-expressing and -deﬁcient cells. As
shown in Figure 5A and B, FANCD2-deﬁcient cells,
either obtained by transient transfection of FANCD2-
speciﬁc siRNA in HeLa cells or derived from an FA
patient, showed a lower production of Ad5 capsid
proteins when compared to their FANCD2-expressing
counterparts. The observed difference could not be
ascribed to a different permissiveness because microscopic
analysis showed the same percentage of infected cells
( 80% for HeLa cells transfected with both siFANCD2
and siLuc and  20% for both FANCD2-expressing and -
deﬁcient cells). The accumulation of E1A seemed similarly
independent of the presence of FANCD2 (Figure 5A
and B), suggesting that the expression of Ad5 early
proteins is not affected by the lack of FANCD2.
The pattern observed at the protein level was conﬁrmed
using quantitative analysis of viral mRNAs using q-PCR
(Figure 5C). Indeed, we observed a similar rate of tran-
scription for the E1A early gene when FANCD2-
expressing cells were compared with FANCD2-deﬁcient
cells (solid lines). However, L1 late gene transcription
showed signiﬁcant differences (Figure 5C, at least 10
times, between 8 and 24 h.p.i., dashed lines). Because the
transcription of Ad5 late genes is strictly dependent upon
the onset of viral DNA replication (51,52), this result
suggests that FANCD2 plays a role in Ad5 replication.
We also assessed viral genome production following the
infection of FANCD2-deﬁcient and -expressing cells using
q-PCR. At early times post-infection, we observed a
10-fold lower quantity of Ad5 in FANCD2-deﬁcient
cells (Figure 5D), consistent with the differences
observed in L1 transcription (Figure 5C). This difference
was gradually lost as the infection progressed. Eventually,
intracellular viral DNA reached a plateau at 28 h.p.i. in
FANCD2-expressing cells, and a similar level was
observed 16h later in FANCD2
 /  cells, demonstrating
that viral production is delayed in FANCD2-deﬁcient
cells.
The viral genome production was also assessed in cells
defective for FANCD2 monoubiquitination (FANCD2
 / 
+K561RFANCD2 and FANCC
 / ) and compared to
their rescued counterpart (Figure 5E). In all cases, we
Nucleic Acids Research, 2011,Vol.39, No. 13 5467observed impaired Ad5 production in FANC-deﬁcient
cells.
Taken together, our data support the hypothesis of a
positive role for monoubiquitinated FANCD2 in Ad5 in-
fection, potentially improving the viral DNA replication
process.
FANCD2 helps Ad5 replication–dependent recombination
Previously published data have implicated the FANC
pathway in replication, homologous recombination and
cell-cycle checkpoints (11,13–15). To shed light on the
function of FANCD2 during Ad5 replication, we
analysed viral DNA replication ﬁdelity and recombination
in Ad5-infected cells.
Because FA cells are characterized by a high degree of
genomic instability, we hypothesized a role for the FANC
pathway in the control of the accuracy of Ad5 replication.
Consequently, the lack of FANCD2 would affect the viral
replication process, leading to mutated and thereby less
infective viral particles. To verify this hypothesis, we
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Figure 5. Lack of FANCD2 affects Ad5 viral production. (A) Viral production analysed using western blot on proteins extracted from Ad5-infected
FANCD2-expressing and FANCD2-siRNA-expressing HeLa cells. Cells were infected with Ad5 at an m.o.i. of 500 OPU 48h after siRNA trans-
fection, and the proteins were extracted at the indicated h.p.i. siLUC: siRNA against luciferase, used as the negative control for transfection;
siFANCD2: siRNA against FANCD2. (B) FANCD2
 /  (PD20) cells and FANCD2-rescued cells (PD20 3.15) were infected with Ad5 at an m.o.i. of
1000 OPU and analysed as in (A). The vertical line indicates areas in which the original blots were cut to eliminate intervening samples. M,
mock-infected cells. (C) Viral mRNA and (D) and (E) viral DNA quantiﬁed using q-PCR. FANC-expressing (FANCD2
+/+) and -deﬁcient
(FANCD2
 / ) cells were infected with Ad5 at an m.o.i. of 1000 OPU. Results are shown as the mean of at least three independent experiments,
and the error bars represent the standard error. Total RNA (C) was extracted at various h.p.i. and analysed using q-PCR to quantify viral
transcription. L1, late protein 1. Total intracellular DNA (D and E) was extracted at various h.p.i. and analysed using q-PCR to quantify viral
replication using oligonucleotides to amplify the E1A region.
5468 Nucleic Acids Research, 2011,Vol.39, No. 13infected FANCD2-deﬁcient and -expressing cells and col-
lected the produced viral particles at 72 h.p.i. The col-
lected virus samples were quantiﬁed using RT-PCR and
HPLC and used to reinfect FANCD2-deﬁcient and -ex-
pressing cells at an equal m.o.i. This procedure was
repeated for three cycles (see scheme in Figure 6A). The
viruses collected and quantiﬁed from each cycle were then
used to infect HeLa cells at the same m.o.i. to determine if
the same amount of viruses produced from cells that ex-
pressed or lacked FANCD2 retained the same infectivity.
We consistently recovered a lower amount of viral par-
ticles from FANCD2-deﬁcient cells (Figure 5 and data
not shown). However, when the same amount of particle
was used for HeLa cell infection, we observed no differ-
ences in the quantity of Ad5 produced from viral particles
isolated from cells with or without FANCD2 (Figure 6B).
The same result was observed independent of time, m.o.i.
or the number of cycles of reinfection in both
FANCD2-deﬁcient and -expressing cells (Figure 6B and
data not shown). This result indicates that the virus
ampliﬁed in cells without FANCD2 is as infective as
that ampliﬁed in cells with FANCD2. Thus, we can rea-
sonably exclude the possibility that FANCD2 recruitment
to viral replication centres is necessary to control the
quality of Ad5 replication.
Ad5 undergoes extensive recombination during infec-
tion of cultured somatic cells (37,53), and although the
virus is thought to use the enzymes from the host cell,
the exact host recombination pathways used during Ad5
infection are still undeﬁned. To analyse the possible in-
volvement of FANCD2 in viral recombination, we used
a recombination assay to analyse recombination during a
mixed infection with Ad2 and Ad5 (54). These viruses are
closely related, but the Ad2 genome has two BamH1 sites
on the left side of the genome, while the Ad5 genome only
has one. Recombination that occurs between these sites
leads to the formation of recombinant fragments that
can be detected using Southern blot hybridisation (see
scheme in Figure 6C and the expected pattern in a repre-
sentative experiment in Figure 6D). Despite loading the
same amount of total DNA from the FANCD2
 /  and
FANCD2-rescued samples (IV and V, 300ng), we consist-
ently observed less DNA in the FANCD2
 /  lane (sum of
the P1, R1, R2 and P2 bands). One possible reason for this
difference could be that part of the viral DNA recovered
from FANC-deﬁcient cells was degraded, and the frag-
ments were therefore too short to be visible on the gel.
To avoid the effect that this would have on the interpret-
ation of the data, we compared the frequency of recom-
bination between different cell lines, calculated as
the percentage of recombinant fragments relative to the
total amount of fragments [100  (R1+R2)/(P1+P2+
R1+R2)]. This quantiﬁcation showed that the frequency
of recombination in FANCD2-expressing cells was more
than 15%. Conversely, a signiﬁcant reduction in the re-
combination frequency (P<0.05) was observed in all ex-
periments with FANCD2
 /  and FANCC
 /  cells
(Figure 6D and E and data not shown). In addition,
FANCD2
 /  cells consistently showed 25–30% less re-
combinants than their corrected counterpart independent
of the m.o.i. used (Figure 6F).
These data suggest that FANCD2 is involved in the
production of recombinant Ad molecules that origin-
ate during viral replication, which could indirectly affect
the accumulation of replicated viral particles. However,
because viral recombination still occurs without
FANCD2, other cellular proteins are most likely involved.
Further research is required to fully characterize the
cellular machinery involved in Ad5 recombination.
DISCUSSION
Deciphering the crosstalk between a host cell and a virus
during infection is important not only to obtain a better
understanding of viral biology but also to improve our
understanding of cellular processes. In this study, we
analysed the interaction of Ad5 with its infected cell as
an alternative means to characterize the activation and
function of the FANC pathway in DNA replication and
recombination. We demonstrate that Ad infection specif-
ically induces FANCD2 monoubiquitination and relocali-
zation to viral replication centres, where it helps viral
recombination and replication.
It has been reported that expression of the HPV-16 E7
oncoprotein or the LT region from SV40, both functional
analogues of E1A, alone leads to the monoubiquitination
of FANCD2 and the formation of FANCD2 foci on
cellular chromatin (40,41). However, our work shows
that the expression of E1A is necessary but not sufﬁcient
to induce the FANC pathway; intact replication-
competent virus is also required. It is important to note
that our ﬁndings are not in opposition with the work of
Spardy et al. (41), who observed FANCD2 monoubiquiti-
nation and focus formation using only the high-risk
HPV-16 E7 oncoprotein, while a low-risk HPV-6 E7
failed to induce these events. Because Ad5 is not onco-
genic in humans, this could mean that the low-risk
HPV-6 E7 is a closer functional analogue of Ad5 E1A.
Our data show that the activation of the FANC
pathway can be uncoupled from the activation of the
DDR. It has been suggested that the Ad-induced DDR
is dependent on the presence of double-stranded termini
sensed as DSBs by the cellular machinery. Our data
conﬁrm this possibility because infection with a
non-replicative double-stranded virus, AdGFP, activates
the DDR. Notwithstanding the possible activation of the
DDR, FANCD2 is not activated, indicating that the
presence of DSBs is not sufﬁcient to activate the FANC
pathway. Interestingly, a recent report from Boichuk et al.
(40) showed that FANCD2 was monoubiquitinated and
relocalized to SV40 viral replication centres in a
DDR-dependent manner (41), contrary to our ﬁndings.
This is not completely unexpected because, contrary to
Ad5, SV40 activates the cellular DDR process to foster
its own replication. Considering that HPV, SV40 and Ad5
were shown to induce FANCD2 monoubiquitination,
FANCD2 can be added to the class of common targets
of viral infections, including p53, pRb and the MRN
complex.
Several of the presented ﬁndings are consistent with a
requirement of activated FANCD2 for optimal viral
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Figure 6. FANCD2 does not affect the outcome of replication but is required for Ad replication-dependent recombination. (A) Schematic repre-
sentation of the experiment in (B). FANCD2-expressing and -deﬁcient cells were infected at the same m.o.i., and supernatants were collected at
72 h.p.i., titrated using q-PCR and HPLC and used to reinfect FANCD2-expressing and -deﬁcient cells at the same m.o.i. This was repeated for three
successive cycles. HeLa cells were infected with the collected and quantiﬁed virus from each cycle using the same m.o.i. (B) HeLa cells were infected
with the collected and quantiﬁed Ad5 virus from the third cycle using an m.o.i. of 20 OPU, and viral production was quantiﬁed using q-PCR at the
indicated time points using oligonucleotides to amplify the E1A region. Results are shown as the mean of at least three independent experiments, and
error bars represent the standard error. (C) Schematic representation of the experiments in (D–F). Recombination (cross) within the region con-
taining the two BamH1 sites (circles) speciﬁc for Ad2 generates two recombinant products, each with only one BamH1 site on the left side of the Ad
genome. The probe (red), directed against the region between the Ad2-speciﬁc BamH1 sites, recognizes the parental fragments P1 and P2 and the
recombinant fragments R1 and R2. (D) Southern blot hybridisation analysis of intracellular DNA from the Ad2 X Ad5 cross that was prepared as
described in ‘Materials and Methods’ section; the data are representative of three different experiments. (Lines I–III) MRC5-infected human SV40
transformed ﬁbroblasts, total m.o.i. 500; line I: Ad5, 60ng; line II: Ad2, 60ng; line III: Ad2+Ad5, 120ng; line IV: Ad2+Ad5 from FANCD2-rescued
infected cells, total m.o.i. 1000, 300ng; line V: Ad2+Ad5 from FANCD2
 /  infected cells, total m.o.i. 1000, 300ng; and M: DIG-labelled marker.
(E) Quantitative analysis of the recombination from three independent experiments as in (D), calculated as the percentage of the recombinant
fragments relative to the total amount of fragments. The error bars represent the standard error of the mean. A signiﬁcant decrease in recombination
was observed in FANCD2-deﬁcient cells compared to FANCD2-rescued cells (P<0.05). No difference was observed between FANCD2-rescued and
wt (MRC5) cells. (F) Quantitative analysis of the recombination in FANCD2
 /  and FANCD2-rescued cells infected with Ad2 and Ad5 at different
m.o.i., treated as indicated in ‘Materials and Methods’ section and analysed using Southern blot as in (E). Results are shown as the mean of three
independent experiments, and error bars represent the standard error.
5470 Nucleic Acids Research, 2011,Vol.39, No. 13replication, including the recruitment of FANCD2 to sites
of active viral replication and delayed viral replication in
the absence of FANCD2. However, FANCD2 is not es-
sential for a productive viral cycle because viral replication
centres can form in the absence of FANCD2 and viral
particles produced in FANCD2-deﬁcient cells are as in-
fective as those produced in FANCD2-expressing cells.
These data are compatible with the hypothesis that
FANCD2 plays a role in Ad5 replication-dependent
recombination. Ad5 recombination proceeds through
both the Holliday and the Meselson and Radding
models for cellular recombination (55) (Figure 7A).
However, the proteins involved in the viral recombination
steps remain elusive. During the recombination of cellular
DNA, the strand exchange step is mediated by RAD51
(56); however, RAD51 involvement in Ad5 recombin-
ation has been excluded (57), and it has been suggested
that viral DBP is able to perform the strand exchange
step (58). We speculated that FANCD2 could interact
with DBP to aid in recombination. However, we
observed normal DBP expression and sub-nuclear local-
ization in FANC-deﬁcient cells. In addition, DBP was not
present in FANCD2 immunoprecipitates (Supplementary
Figure S1C). Therefore, it is possible that FANCD2 inter-
acts with other viral proteins or directly binds to viral
DNA. Consistent with the latter hypothesis, data from
Sobeck et al. (59) have shown the capacity of FANCD2
to bind directly naked DNA. Our data demonstrate that
the frequency of recombinant viral particles in mixed in-
fections is signiﬁcantly reduced (30%, P<0.05) in the
absence of the FANC pathway. We therefore propose
that FANCD2 facilitates the completion of recombination
(Figure 7A); its absence could either delay or prevent this
process, limiting the accessibility of double-stranded viral
genomes to replication machinery. In this scenario,
FANCD2 seems to play an opposite role to that of
BLM. Indeed, the helicase mutated in Bloom syndrome
has been proposed to limit recombination, and in its
absence, Ad5 recombination has been reported to be
increased (60).
The adenoviral system provides an alternative means to
analyse the mechanism and the consequences of FANC
pathway activation.
Previous studies (10,12,45,59,61,62) suggest that
FANCD2 monoubiquitination follows three pathways
(Figure 7B): one that is ATR-dependent but CHK1-
independent, which is probably activated by endogenous
replication stress associated with CHK1 deﬁciency, and
another pathway that is ATR- and CHK1-dependent
and that is activated in response to replication problems
induced by exogenous DNA damage. A third mechanism,
induced by either cellular (59,61,62) or viral (our data)
DNA replication, leads to FANCD2 monoubiquitination
independent of both ATR and CHK1 (Figure 7B). This
pathway could be exclusively involved in dealing with
intrinsic problems that arise during normal replication.
In conclusion, we believe that our results have import-
ant implications for the use of oncolytic viruses in cancer
therapy, in which Ad5 is one of the most-used viruses. In
fact, numerous studies have reported synergy between
oncolytic Ad5 and chemotherapeutic drugs, such as
cisplatin, a well-known activator of the FANC pathway
(63–65). No molecular mechanism has been elucidated to
explain these results, but there is evidence suggesting that
the interaction of the virus with the DNA repair machin-
ery could be involved. Our ﬁnding that FANCD2 re-
cruited to Ad5 replication centres cannot relocalize to
sites of cellular damage, possibly interfering with
FANCD2 function, should be taken into account when
deciphering the observed synergy.
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